Open AccessPerioperative plasma glypican-3 level may enable prediction of the risk of recurrence after surgery in patients with stage I hepatocellular carcinoma
Author(s) -
Kazuya Ofuji,
Keigo Saito,
Shiro Suzuki,
Manami Shimomura,
Hirofumi Soejima,
Daisuke Nobuoka,
Yu Sawada,
Masao Yoshimura,
Nobuhiro Tsuchiya,
Mari Takahashi,
Toshiaki Yoshikawa,
Yoshitaka Tada,
Masaru Konishi,
Shinichiro Takahashi,
Naoto Gotohda,
Yasunari Nakamoto,
Tetsuya Nakatsura
Publication year - 2016
Publication title -
oncotarget
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.373
H-Index - 127
ISSN - 1949-2553
DOI - 10.18632/oncotarget.14271
Subject(s) - perioperative , hepatocellular carcinoma , medicine , glypican 3 , stage (stratigraphy) , oncology , plasma levels , surgery , urology , biology , paleontology
Glypican-3 (GPC3) is a glycosylphosphatidylinositol-anchored cell surface protein overexpressed in hepatocellular carcinoma(HCC), and its overexpression is associated with poor prognosis. The diagnostic potential of GPC3 as a serum marker has been reported. In the present study, we evaluated the usefulness of plasma GPC3 as a predictor for recurrence after surgical resection in stage I HCC patients by newly developed an enzyme-linked immunosorbent assay (ELISA) system. Current study demonstrated that high levels of preoperative plasma GPC3 patients tended to experience postoperative recurrence. On the other hand, pre- and postoperative plasma GPC3 positivity of non-recurrence patients was very low. Moreover, even after surgery, approximately half of patients who experienced recurrence were positive for plasma GPC3. Postoperative plasma GPC3 positivity was significantly correlated with worse recurrence-free survival. Immuohistochemical analysis also showed positive rate of GPC3-expression in HCC was higher in recurrence patients than in non-recurrence patients. These results suggested that both pre- and postoperative plasma GPC3 levels may be accurate predictors for recurrence after curative resection of early-stage HCC. It should be noted that the current study only examined a small number of cases; thus, a larger sample size is necessary to validate GPC3 as a predictor for HCC recurrence.